Isolagen, Inc., a biopharmaceutical company, announced that it has received preliminary positive results from the dental study conducted at the University of Texas Health Science Center Dental Branch (UTHSC).

The Isolagen dental study is being conducted at UTHSC with 21 patients. Dr Otis Bouwsma, associate professor at UTHSC, was the principal investigator in Isolagen's dental clinical study. Dr Otis Bouwsma stated, "On a preliminary review of the data of the triple blind study, it is clear the patients we assume received Isolagen have had significant improvements in the two areas of treatment: the deep pocket areas and in the gingival recession areas. A benefit of up to 4 mm was seen is some of the deep pocket areas. This autologous cellular treatment may potentially play a huge role in the way gum recession is treated in the future. The blind on this study will be lifted at the end of December 2003 so a full quantitative data analysis and report will be available in the first quarter of 2004. With what I have seen from a clinical perspective from administrating the procedures chair-side, I am highly encouraged by these preliminary results."

Mike Macaluso, CEO of Isolagen, stated, "Though the UTHSC observations are preliminary, we are very encouraged by these observations and we plan to move forward to start the design of what we hope will be our final Phase III dental study to the United States Food and Drug Administration."